Pharmaceutical research equipment manufacturer Brammer Bio Fisher has expanded in the gene therapy space with its $1.7bn acquisition of viral vector maker Thermo from Ampersand Capital Partners. Brammer Bio CEO Marc Casper said official takeover talks began earlier this year and the two firms were already collaborating on some services. Brammer Bio anticipates Brammer's 2019 total revenue will be $250m. The gene therapy contract development and manufacturing market is currently worth $1bn and is growing at more than 25% annually, Casper added.
Pharmaceutical research equipment manufacturer Thermo Fisher has expanded in the gene therapy space with its $1.7bn acquisition of viral vector maker Brammer Bio from Ampersand Capital Partners. Thermo CEO Marc Casper said official takeover talks began earlier this year and the two firms were already collaborating on some services. Thermo anticipates Brammer's 2019 total revenue will be $250m. The gene therapy contract development and manufacturing market is currently worth $1bn and is growing at more than 25% annually, Casper added.